NASDAQ:HSIC - Henry Schein Stock Price, News, & Analysis

Henry Schein trades on the NASDAQ under the ticker symbol "HSIC."

Henry Schein shares split before market open on Friday, September 15th 2017. The 2-1 split was announced on Wednesday, August 16th 2017. The newly minted shares were issued to shareholders after the market closes on Thursday, September 14th 2017. An investor that had 100 shares of Henry Schein stock prior to the split would have 200 shares after the split.

Henry Schein announced that its Board of Directors has initiated a share buyback plan on Tuesday, September 19th 2017, which permits the company to buyback $400,000,000.00 in outstanding shares, according to EventVestor. This buyback authorization permits the company to reacquire up to 6.3% of its shares through open market purchases. Shares buyback plans are typically a sign that the company's board of directors believes its stock is undervalued.

Henry Schein, Inc. (NASDAQ:HSIC) announced its quarterly earnings results on Tuesday, November, 6th. The company reported $1.03 earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of $1.01 by $0.02. The business earned $3.28 billion during the quarter, compared to analyst estimates of $3.37 billion. Henry Schein had a return on equity of 20.40% and a net margin of 3.00%. Henry Schein's revenue was up 3.8% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $0.87 earnings per share. View Henry Schein's Earnings History.

Henry Schein is scheduled to release their next quarterly earnings announcement on Tuesday, February 19th 2019. View Earnings Estimates for Henry Schein.

Henry Schein issued an update on its FY18 earnings guidance on Tuesday, November, 6th. The company provided earnings per share guidance of $4.06-4.14 for the period, compared to the Thomson Reuters consensus estimate of $4.12.

16 brokerages have issued 1-year target prices for Henry Schein's shares. Their forecasts range from $66.00 to $102.00. On average, they expect Henry Schein's stock price to reach $85.6429 in the next year. This suggests a possible upside of 0.6% from the stock's current price. View Analyst Price Targets for Henry Schein.

16 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Henry Schein in the last year. There are currently 2 sell ratings, 6 hold ratings and 8 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Henry Schein.

News articles about HSIC stock have been trending positive recently, InfoTrie Sentiment reports. The research group identifies positive and negative press coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Henry Schein earned a media sentiment score of 2.1 on InfoTrie's scale. They also gave news coverage about the company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an impact on the company's share price in the next several days.

Some companies that are related to Henry Schein include Allergan (AGN), Boston Scientific (BSX), Celgene (CELG), Illumina (ILMN), HCA Healthcare (HCA), Vertex Pharmaceuticals (VRTX), Zoetis (ZTS), Humana (HUM), Regeneron Pharmaceuticals (REGN), Baxter International (BAX), Edwards Lifesciences (EW), Actelion (ALIOF), ASTELLAS PHARMA/ADR (ALPMY), Centene (CNC) and ESSILOR Intl S/S (ESLOY).

Henry Schein's stock is owned by a number of of retail and institutional investors. Top institutional investors include Vanguard Group Inc. (10.67%), Longview Partners Guernsey LTD (8.92%), BlackRock Inc. (6.94%), FMR LLC (5.69%), Select Equity Group L.P. (4.08%) and Brown Brothers Harriman & Co. (3.40%). Company insiders that own Henry Schein stock include Barry J Alperin, David Mckinley, Donald J Kabat, Gerald A Benjamin, James A Harding, Kurt P Kuehn, Lorelei Mcglynn, Mark E Mlotek, Michael Racioppi, Michael S Ettinger, Paul Brons, Paul Rose, Philip A Laskawy, Stanley M Bergman and Steven Paladino. View Institutional Ownership Trends for Henry Schein.

HSIC stock was sold by a variety of institutional investors in the last quarter, including Janus Henderson Group PLC, Mackenzie Financial Corp, Deutsche Bank AG, Alecta Pensionsforsakring Omsesidigt, Select Equity Group L.P., Brown Brothers Harriman & Co., Schroder Investment Management Group and JPMorgan Chase & Co.. Company insiders that have sold Henry Schein company stock in the last year include David Mckinley, Mark E Mlotek, Paul Brons, Stanley M Bergman and Steven Paladino. View Insider Buying and Selling for Henry Schein.

HSIC stock was bought by a variety of institutional investors in the last quarter, including FMR LLC, Atlanta Capital Management Co. L L C, Morgan Stanley, AXA, American Century Companies Inc., WINTON GROUP Ltd, Ancora Advisors LLC and First Trust Advisors LP. View Insider Buying and Selling for Henry Schein.

Shares of HSIC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of HSIC stock can currently be purchased for approximately $85.16.

Henry Schein has a market capitalization of $12.98 billion and generates $12.46 billion in revenue each year. The company earns $406.29 million in net income (profit) each year or $3.60 on an earnings per share basis. Henry Schein employs 22,000 workers across the globe.

The official website for Henry Schein is http://www.henryschein.com.

Henry Schein's mailing address is 135 DURYEA RD, MELVILLE NY, 11747. The company can be reached via phone at 631-843-5500 or via email at [email protected]